ENTITY

InflaRx NV (IFRX US)

Analysis

Health Care • United States

InflaRx N.V. operates as a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies drugs for the treatment of inflammatory diseases. InflaRx serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00